[Adoptive immunotherapy with interleukin 2. Initial results of a pilot study in 6 cancer patients].
Adoptive immunotherapy of cancer consists of using interleukin-2 to induce the formation of lymphokine-activated killer (LAK) cells which are toxic to tumoral cells. Six patients, 3 with hypernephroma and 3 with melanoma, were treated with interleukin-2. Drug toxicity consisted of capillary leakage syndrome in one case and reversible renal impairment in another. One patient showed an objective response; transient subjective improvement was observed in all patients.
Sculier
J P
JP
Service de Médecine, Institut Jules Bordet, Université libre de Bruxelles, Belgique.
Bron
D
D
Delforge
A
A
Body
J J
JJ
Verboven
N
N
Frühling
J
J
Stryckmans
P
P
Klastersky
J
J
D058186:Acute Kidney Injury / Q000139:chemically induced; D000328:Adult; D000368:Aged; D002199:Capillary Permeability / Q000187:drug effects; D002292:Carcinoma, Renal Cell / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007116:Immunization, Passive / Q000379:methods*; D007376:Interleukin-2 / Q000009:adverse effects / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000628:therapy*; D007694:Killer Cells, Natural; D008297:Male; D008545:Melanoma / Q000628:therapy*; D008875:Middle Aged
D007376:Interleukin-2
Immunothérapie adoptive par interleukine-2. Premiers résultats d'une étude pilote chez 6 malades cancéreux.